Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Update

Aptevo Therapeutics Inc. (NASDAQ:APVO) saw a large growth in short interest in March. As of March 15th, there was short interest totalling 28,900 shares, a growth of 725.7% from the February 29th total of 3,500 shares. Based on an average daily trading volume, of 91,700 shares, the days-to-cover ratio is currently 0.3 days. Approximately 5.5% of the shares of the company are short sold.

Aptevo Therapeutics Stock Performance

Shares of APVO stock opened at $4.69 on Friday. Aptevo Therapeutics has a 12-month low of $3.81 and a 12-month high of $92.62. The firm’s 50 day moving average is $6.08 and its 200 day moving average is $9.21.

Hedge Funds Weigh In On Aptevo Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of APVO. Sabby Management LLC purchased a new stake in Aptevo Therapeutics during the third quarter valued at $440,000. Armistice Capital LLC bought a new stake in shares of Aptevo Therapeutics during the 3rd quarter valued at about $408,000. Citadel Advisors LLC purchased a new stake in shares of Aptevo Therapeutics during the 4th quarter valued at about $47,000. Cantor Fitzgerald L. P. lifted its stake in shares of Aptevo Therapeutics by 14.8% in the 2nd quarter. Cantor Fitzgerald L. P. now owns 251,122 shares of the biotechnology company’s stock worth $367,000 after purchasing an additional 32,422 shares during the period. Finally, Bank of New York Mellon Corp bought a new position in shares of Aptevo Therapeutics in the 1st quarter worth approximately $152,000. 8.06% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on Aptevo Therapeutics in a research report on Monday. They issued a “hold” rating for the company.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and.